| Name | 4-{[(1R,3S)-3-Amino-2,2,3-trimethylcyclopentyl]amino}-6-(6-methoxy-3-pyridinyl)pyrrolo[1,2-b]pyridazine-3-carboxamide |
|---|---|
| Synonyms |
4-{[(1R,3S)-3-Amino-2,2,3-trimethylcyclopentyl]amino}-6-(6-methoxy-3-pyridinyl)pyrrolo[1,2-b]pyridazine-3-carboxamide
Pyrrolo[1,2-b]pyridazine-3-carboxamide, 4-[[(1R,3S)-3-amino-2,2,3-trimethylcyclopentyl]amino]-6-(6-methoxy-3-pyridinyl)- |
| Description | JAK-IN-35 is a potent and efficacious dual JAK1/JAK3 inhibitor with IC50 of 0.9/1.9 nM; shows weak activity against TYK2 and JAK2 (IC50=25 nM and15 nM respectively), also inhibits both ROCK1 (IC50=95 nM) and ROCK2 (IC50=43 nM); inhibits JAK1/3 mediated ex vivo processes in the mouse PD model (EC50 67 ± 13 nM); shows potential cardiovascular liabilities, specifically, QT interval prolongation. |
|---|---|
| References | References 1. Hynes J Jr, et al. Bioorg Med Chem Lett. 2017 Jul 15;27(14):3101-3106. View Related Products by Target JAK |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Molecular Formula | C22H28N6O2 |
| Molecular Weight | 408.497 |
| Exact Mass | 408.227386 |
| LogP | 2.63 |
| Index of Refraction | 1.673 |